title: Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication.
abstract: Obesity is one of the most serious common somatic adverse effects of atypical antipsychotic agents. Genetic factors partly determine the individual patients risk of developing obesity during treatment. As weight-regulating mechanisms, such as the leptinergic and serotonergic system, may be interdependent, genetic polymorphisms in these systems also may show interactions. To determine whether combined HTR2CLEP genotype or HTR2C-LEPR genotype are associated with obesity in patients using atypical antipsychotic drugs, a cross-sectional study design was used. The study population included 200 patients aged between 18 and 65 years of age, diagnosed with a psychotic disorder, all of whom had been using an atypical antipsychotic for at least 3 months. Primary outcome measure was presence of obesity (body mass index, >30). Determinants were the combined (HTR2C -759C/T-LEPR Q223R), (HTR2C -759C/T-LEP -2548G/A, (HTR2C rs1414334-LEPR Q223R) and (HTR2C rs1414334-LEP -2548G/A) genotypes. Of the 200 included patients, 61 (31%) were obese. In patients without the HTR2C -759T allele, presence of the LEP -2548G allele was associated with obesity (odds ratio, 2.88; 95% confidence interval, 1.05-7.95). The results of the other analyses showed some nonsignificant trends. The combined (HTR2C -759C/TYLEP -2548G/A) genotype may be a determinant of obesity in patients during treatment with atypical antipsychotic drugs.
authors.affiliation: Psychiatric Hospital Meerkanten, Ermelo, The Netherlands.
authors.forename: Jochem G
authors.initials: JG
authors.lastname: Gregoor
authors.forename: Hans
authors.initials: H
authors.lastname: Mulder
authors.forename: Dan
authors.initials: D
authors.lastname: Cohen
authors.forename: Harold J G M
authors.initials: HJ
authors.lastname: van Megen
authors.forename: Toine C G
authors.initials: TC
authors.lastname: Egberts
authors.forename: Eibert R
authors.initials: ER
authors.lastname: Heerdink
authors.forename: Jan
authors.initials: J
authors.lastname: van der Weide
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D020738:Leptin / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000235:genetics; D011110:Polymorphism, Genetic; D011618:Psychotic Disorders / Q000188:drug therapy; D044405:Receptor, Serotonin, 5-HT2C / Q000235:genetics*; D054411:Receptors, Leptin / Q000235:genetics; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D020738:Leptin; D044405:Receptor, Serotonin, 5-HT2C; D054411:Receptors, Leptin